Navigation Links
Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results
Date:11/17/2009

LAIYANG, China, Nov. 17 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) ("Jiangbo" or the "Company"), a pharmaceutical company with its principal operations in the People's Republic of China, today announced its financial results for its first quarter of fiscal year 2010 ended September 30, 2009.

    First Quarter Fiscal Year 2010 Highlights:
    -- Revenues were $24.4 million
    -- Gross profit was $18.1 million
    -- Operating income rose 72.6% year-over-year to $12.7 million compared to
       $7.3 million in the first quarter of fiscal year 2009
    -- Net income was $2.0 million, or $0.18 per fully diluted share
    -- Excluding non-cash expenses related to the change in fair value from
       derivative liabilities of $4.8 million and the amortization of debt
       discount and debt issuance costs related to convertible debentures of
       $2.3 million, non-GAAP adjusted net income was $9.1 million, or $0.60
       per fully diluted share for the three months ended September 30, 2009,
       up 128.5% from non-GAAP adjusted net income of $4.0 million, or $0.28
       per fully diluted share, for the quarter ended September 30, 2008.(*)

"Our first quarter fiscal 2010 results reflect the restructuring of our distribution and sales system, which we began in January 2009," said Mr. Wubo Cao, Chairman and Chief Executive Officer. "Although summer is usually the slowest season for our sales, we believe that we were able to still achieve strong growth in our operating income as we efficiently managed our selling and marketing expenses. We believe that our strong cash position will provide us with significant flexibility to pursue continued organic growth and strategic acquisitions."

First Quarter Results

Total revenue was $24.4 million, an 11.5% decrease compared to $27.6 million for the first quarter of 2009. While the quantities sold for
'/>"/>

SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... July 7, 2015   Decision Resources Group ... in dialysis patient management in the U.S. versus ... by U.S. and EU5 nephrologists from approximately 1,870 ... are the most commonly used renal medications in ... differs considerably between the two regions.      ...
(Date:7/7/2015)... FRANCISCO , July 7, 2015 ... reach USD 1,197.7 million by 2020, growing at an estimated ... new study by Grand View Research, Inc. Introduction of innovative ... coupled with growing awareness levels pertaining to the advantages of ... the next six years. In addition, presence of untapped growth ...
(Date:7/7/2015)... , July 7, 2015 EnteroMedics Inc. ... devices that use neuroblocking technology to treat obesity, metabolic ... its previously announced public offering of 32,000,000 units. Each unit ... Series A warrant to purchase one share of common ... Investors whose purchase of units in the offering would ...
Breaking Medicine Technology:Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 2Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 3Breast Pumps Market To Reach $1,197.7 Million By 2020: Grand View Research, Inc. 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3
... CHICAGO and ORANGE, Calif., Feb. 23, 2011 ... (SJHS), a $4.6 billion not-for-profit Catholic healthcare system based in ... in California, West Texas and Eastern New Mexico, has selected ... MDRX ) to streamline patient movement through their ...
... Caliper Life Sciences, Inc. (Nasdaq: ... announced a co-marketing agreement which will leverage Covaris, ... microfluidics technologies to develop automated workflows for next ... suite of solutions for library construction, sample analysis, ...
Cached Medicine Technology:St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 2St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 3St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 4St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions 5Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 2Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing 3
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... development and growth strategy expert Jay Warden as Senior Vice President, heading the ... company’s efforts to provide the best solutions to healthcare providers’ needs in ways ...
(Date:7/7/2015)... Dallas, TX (PRWEB) , ... July 07, 2015 , ... Ticket Down is a reputable ... Panama vs. Haiti and the United States vs. Honduras at the Toyota Stadium. ... today, July 7th at Toyota Stadium. The tournament, being held on American soil, will ...
(Date:7/7/2015)... ... ... Greatist today announced the acquisition of Blood, Sweat & ... fun activities to do with friends. , The acquisition of BSC strengthens Greatist’s leadership ... events, e-commerce, and brand partnerships. , “I’ve been a huge fan of Blood, Sweat ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... global provider of advanced delivery technologies and development solutions for drugs, biologics ... licensing agreement with Excelimmune, Inc. to access its antibody combination therapy (ACT) ...
(Date:7/7/2015)... ... ... Healthpointe is proud to announce the addition of Dr. Pedro S. ... will be evaluating and treating patients with orthopedic complaints, such as lumbar back pain ... Science in Biology from the University of the East, Manila, Dr. Alupay earned his ...
Breaking Medicine News(10 mins):Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 2Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 3Health News:Panama vs Haiti & USA vs Honduras CONCACAF Group A Tickets at Toyota Stadium: Ticket Down Slashes Ticket Prices for Haiti vs Panama & USA vs Honduras in Frisco/Dallas 2Health News:Panama vs Haiti & USA vs Honduras CONCACAF Group A Tickets at Toyota Stadium: Ticket Down Slashes Ticket Prices for Haiti vs Panama & USA vs Honduras in Frisco/Dallas 3Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 3
... of Genetic research has indeed unleashed several social and moral ... within themselves.// However, it has also managed to shed new ... recent announcement made by a U.S research team from the ... the understanding of genes which many think; may be ...
... exercise is just as good at beating mild to moderate ... five different exercise programs for people with mild to moderate ... among those taking part in aerobic exercises like walking on ... study involved 80 people with mild to moderate depression who ...
... Heart disease is at least six-times more likely to kill ... researchers based on findings of a recent study . ... high risk because of diabetes or multiple risk factors were ... how doctors managed their cholesterol levels. ,Researchers found only ...
... girls are affected more than boys. Researchers say sex-linked // ... diagnosed with type 2 diabetes. ,Researchers are in the ... children are insulin-resistant and why. The study included 307 healthy ... until they are 16 years old. Researchers are keeping track ...
... Researchers say adding radiation therapy to a treatment regimen ... leads to better survival outcomes among women with high-risk ... ,Ina study done between 1979 and 1986, 318 ... no radiation at all. In a 20-year follow-up, researchers ...
... heart disease risk factors may reduce the risk of ... study // which shows that cardiovascular risk factors in ... in old age. ,Risk factors for cardiovascular ... of these cardiovascular risk factors identified at midlife (ages ...
Cached Medicine News:
... Practice management software for ... a true multi-tasking, multi-office practice ... in database technology- Winx Pro ... will assist you in effectively ...
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The SE-9000 automated hematology analyzer provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test results for enhanced screening ability....
... offers three-dimensional VCS technology, ... and efficiency in white ... analysis. With its reputation ... HmX is an affordable ...
Medicine Products: